765 related articles for article (PubMed ID: 27926730)
1. Integrin-YAP/TAZ-JNK cascade mediates atheroprotective effect of unidirectional shear flow.
Wang L; Luo JY; Li B; Tian XY; Chen LJ; Huang Y; Liu J; Deng D; Lau CW; Wan S; Ai D; Mak KK; Tong KK; Kwan KM; Wang N; Chiu JJ; Zhu Y; Huang Y
Nature; 2016 Dec; 540(7634):579-582. PubMed ID: 27926730
[TBL] [Abstract][Full Text] [Related]
2. Flow-dependent YAP/TAZ activities regulate endothelial phenotypes and atherosclerosis.
Wang KC; Yeh YT; Nguyen P; Limqueco E; Lopez J; Thorossian S; Guan KL; Li YJ; Chien S
Proc Natl Acad Sci U S A; 2016 Oct; 113(41):11525-11530. PubMed ID: 27671657
[TBL] [Abstract][Full Text] [Related]
3. Atheroprotective effects of methotrexate via the inhibition of YAP/TAZ under disturbed flow.
Liu D; Lv H; Liu Q; Sun Y; Hou S; Zhang L; Yang M; Han B; Wang G; Wang X; Du W; Nie H; Zhang R; Huang X; Hou J; Yu B
J Transl Med; 2019 Nov; 17(1):378. PubMed ID: 31730006
[TBL] [Abstract][Full Text] [Related]
4. Laminar flow inhibits the Hippo/YAP pathway via autophagy and SIRT1-mediated deacetylation against atherosclerosis.
Yuan P; Hu Q; He X; Long Y; Song X; Wu F; He Y; Zhou X
Cell Death Dis; 2020 Feb; 11(2):141. PubMed ID: 32081881
[TBL] [Abstract][Full Text] [Related]
5. Biomimetic nanodrug targets inflammation and suppresses YAP/TAZ to ameliorate atherosclerosis.
Huang HC; Wang TY; Rousseau J; Orlando M; Mungaray M; Michaud C; Plaisier C; Chen ZB; Wang KC
Biomaterials; 2024 Apr; 306():122505. PubMed ID: 38359507
[TBL] [Abstract][Full Text] [Related]
6. Salvianolic acid B ameliorates atherosclerosis via inhibiting YAP/TAZ/JNK signaling pathway in endothelial cells and pericytes.
Yang Y; Pei K; Zhang Q; Wang D; Feng H; Du Z; Zhang C; Gao Z; Yang W; Wu J; Li Y
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Oct; 1865(10):158779. PubMed ID: 32739616
[TBL] [Abstract][Full Text] [Related]
7. Piezo1 mediates endothelial atherogenic inflammatory responses via regulation of YAP/TAZ activation.
Yang Y; Wang D; Zhang C; Yang W; Li C; Gao Z; Pei K; Li Y
Hum Cell; 2022 Jan; 35(1):51-62. PubMed ID: 34606042
[TBL] [Abstract][Full Text] [Related]
8. Targeting the Hippo Signaling Pathway for Tissue Regeneration and Cancer Therapy.
Juan WC; Hong W
Genes (Basel); 2016 Aug; 7(9):. PubMed ID: 27589805
[TBL] [Abstract][Full Text] [Related]
9. Activation of Yes-Associated Protein/PDZ-Binding Motif Pathway Contributes to Endothelial Dysfunction and Vascular Inflammation in AngiotensinII Hypertension.
Xu Q; Zhuo K; Cai R; Su X; Zhang L; Liu Y; Zhu L; Ren F; Zhou MS
Front Physiol; 2021; 12():732084. PubMed ID: 34650444
[TBL] [Abstract][Full Text] [Related]
10. Evolution of mechanotransduction via YAP/TAZ in animal epithelia.
Elbediwy A; Thompson BJ
Curr Opin Cell Biol; 2018 Apr; 51():117-123. PubMed ID: 29477107
[TBL] [Abstract][Full Text] [Related]
11. Distinctive Roles of YAP and TAZ in Human Endothelial Progenitor Cells Growth and Functions.
Klaihmon P; Lorthongpanich C; Kheolamai P; Luanpitpong S; Issaragrisil S
Biomedicines; 2022 Jan; 10(1):. PubMed ID: 35052826
[TBL] [Abstract][Full Text] [Related]
12. Relationship between Keloid Formation and YAP/TAZ Signaling.
Aramaki-Hattori N; Okabe K; Hamada M; Takato T; Kishi K
Plast Reconstr Surg Glob Open; 2017 Jun; 5(6):e1357. PubMed ID: 28740772
[TBL] [Abstract][Full Text] [Related]
13. YAP/TAZ: a promising target for squamous cell carcinoma treatment.
Dong X; Meng L; Liu P; Ji R; Su X; Xin Y; Jiang X
Cancer Manag Res; 2019; 11():6245-6252. PubMed ID: 31360073
[TBL] [Abstract][Full Text] [Related]
14. The regulation of yes-associated protein/transcriptional coactivator with PDZ-binding motif and their roles in vascular endothelium.
Zhang W; Li QQ; Gao HY; Wang YC; Cheng M; Wang YX
Front Cardiovasc Med; 2022; 9():925254. PubMed ID: 35935626
[TBL] [Abstract][Full Text] [Related]
15. Lesion-specific suppression of YAP/TAZ by biomimetic nanodrug ameliorates atherosclerosis development.
Huang HC; Wang TY; Rousseau J; Mungaray M; Michaud C; Plaisier C; Chen ZB; Wang KC
bioRxiv; 2023 Apr; ():. PubMed ID: 37163067
[TBL] [Abstract][Full Text] [Related]
16. Yes-associated protein (YAP) and transcriptional coactivator with a PDZ-binding motif (TAZ): a nexus between hypoxia and cancer.
Zhao C; Zeng C; Ye S; Dai X; He Q; Yang B; Zhu H
Acta Pharm Sin B; 2020 Jun; 10(6):947-960. PubMed ID: 32642404
[TBL] [Abstract][Full Text] [Related]
17. AR activates YAP/TAZ differentially in prostate cancer.
Salem O; Jia S; Qian BZ; Hansen CG
Life Sci Alliance; 2023 Sep; 6(9):. PubMed ID: 37385752
[TBL] [Abstract][Full Text] [Related]
18. Small molecules inhibiting the nuclear localization of YAP/TAZ for chemotherapeutics and chemosensitizers against breast cancers.
Oku Y; Nishiya N; Shito T; Yamamoto R; Yamamoto Y; Oyama C; Uehara Y
FEBS Open Bio; 2015; 5():542-9. PubMed ID: 26199863
[TBL] [Abstract][Full Text] [Related]
19. [Role of Hippo-YAP/TAZ signaling pathway in mechanotransduction.].
Ishihara E; Nishina H
Clin Calcium; 2016; 26(12):1751-1756. PubMed ID: 27885187
[TBL] [Abstract][Full Text] [Related]
20. Curaxin CBL0137 inhibits endothelial inflammation and atherogenesis via suppression of the Src-YAP signalling axis.
Ding H; Jiang M; Lau CW; Luo J; Chan AM; Wang L; Huang Y
Br J Pharmacol; 2023 Apr; 180(8):1168-1185. PubMed ID: 36495259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
